sofosbuvir/velpatasvir / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 20 Diseases   29 Trials   29 Trials   1253 News 


«12...891011121314151617181920»
  • ||||||||||  tacrolimus / Generic mfg.
    DIRECT ACTING ANTI-VIRAL PROPHYLAXIS TO PREVENT VIRUS TRANSMISSION FROM HEPATITIS C VIREMIC DONORS TO HEPATITIS C NEGATIVE KIDENEY TRANSPLANT RECIPIENTS () -  Jan 28, 2020 - Abstract #DDW2020DDW_2803;    
    Ultra-short duration (2-4 days peri-operative) DAA prophylaxis using pangenotypic sofosbuvir/velpatasvir (SOF/VEL) in D+/R- KT was able to prevent HCV transmission in a majority (88%) but not all, KT...All pts received standard of care induction rabbit anti-thymocyte globulin followed by triple immunosuppression with tacrolimus, mycophenolate and prednisone... Our data suggests that 7-day DAA prophylaxis largely effective in preventing donor-derived HCV transmission and could result in significant cost-savings and increase access to these transplants all over the world
  • ||||||||||  Enrollment open:  KeY Treat: The Kentucky Viral Hepatitis Treatment Study (clinicaltrials.gov) -  Jan 22, 2020   
    P4,  N=900, Recruiting, 
    Our data suggests that 7-day DAA prophylaxis largely effective in preventing donor-derived HCV transmission and could result in significant cost-savings and increase access to these transplants all over the world Not yet recruiting --> Recruiting
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  HCV Post-Exposure Prophylaxis for Health Care Workers (clinicaltrials.gov) -  Jan 21, 2020   
    P4,  N=0, Withdrawn, 
    Active, not recruiting --> Completed N=60 --> 0 | Trial completion date: Jul 2023 --> Jan 2020 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2022 --> Jan 2020
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Trial primary completion date:  A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic (clinicaltrials.gov) -  Jan 9, 2020   
    P4,  N=20, Active, not recruiting, 
    N=60 --> 0 | Trial completion date: Jul 2023 --> Jan 2020 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2022 --> Jan 2020 Trial primary completion date: Nov 2019 --> Feb 2020
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Trial completion date, Trial primary completion date:  Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection (clinicaltrials.gov) -  Dec 10, 2019   
    P4,  N=75, Recruiting, 
    Trial completion date: Jun 2019 --> Jun 2021 | Trial primary completion date: Jun 2019 --> Jul 2020 Trial completion date: Feb 2021 --> Jul 2021 | Trial primary completion date: Feb 2020 --> Jul 2020
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Enrollment change:  SToP-C: Surveillance and Treatment of Prisoners With Hepatitis C (clinicaltrials.gov) -  Dec 9, 2019   
    P4,  N=3692, Completed, 
    Trial completion date: Feb 2021 --> Jul 2021 | Trial primary completion date: Feb 2020 --> Jul 2020 Recruiting --> Completed | N=2500 --> 3692
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Trial completion date, Trial initiation date, Trial primary completion date:  The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study (clinicaltrials.gov) -  Nov 15, 2019   
    P4,  N=150, Not yet recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Nov 2019 --> Nov 2020 | Trial primary completion date: Nov 2019 --> Nov 2020 Trial completion date: Sep 2021 --> Dec 2021 | Initiation date: Sep 2019 --> Jan 2020 | Trial primary completion date: Jun 2021 --> Oct 2021
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Trial completion date, Trial primary completion date:  Expanding the Pool in Orthotopic Heart Transplantation (clinicaltrials.gov) -  Oct 14, 2019   
    P2,  N=20, Recruiting, 
    Trial completion date: Sep 2021 --> Dec 2021 | Initiation date: Sep 2019 --> Jan 2020 | Trial primary completion date: Jun 2021 --> Oct 2021 Trial completion date: Jul 2019 --> Jul 2023 | Trial primary completion date: Jul 2019 --> Jul 2023
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Enrollment closed, Trial primary completion date:  A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic (clinicaltrials.gov) -  Sep 17, 2019   
    P4,  N=20, Active, not recruiting, 
    With the advent of effective DAA, HCV can be eradicated universally with no serious adverse effects. Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2019 --> Nov 2019
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Post-transplantation:  Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment (clinicaltrials.gov) -  Sep 11, 2019   
    P4,  N=1, Terminated, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2019 --> Nov 2019 N=10 --> 1 | Trial completion date: Sep 2019 --> Mar 2019 | Recruiting --> Terminated | Trial primary completion date: Sep 2019 --> Mar 2019; Enrollment terminated due to not having any other eligible participants.
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Enrollment open:  The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients (clinicaltrials.gov) -  Sep 9, 2019   
    P2,  N=60, Enrolling by invitation, 
    N=10 --> 1 | Trial completion date: Sep 2019 --> Mar 2019 | Recruiting --> Terminated | Trial primary completion date: Sep 2019 --> Mar 2019; Enrollment terminated due to not having any other eligible participants. Not yet recruiting --> Enrolling by invitation
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Enrollment open, Trial completion date, Trial primary completion date:  HCV Post-Exposure Prophylaxis for Health Care Workers (clinicaltrials.gov) -  Aug 14, 2019   
    P4,  N=60, Recruiting, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2020 --> Dec 2020 Not yet recruiting --> Recruiting | Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Dec 2021 --> Dec 2022
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date:  The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients (clinicaltrials.gov) -  Aug 14, 2019   
    P2,  N=20, Recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Dec 2021 --> Dec 2022 Not yet recruiting --> Recruiting | Trial completion date: Feb 2024 --> May 2024 | Initiation date: Feb 2019 --> Aug 2019 | Trial primary completion date: Feb 2024 --> May 2024
  • ||||||||||  tacrolimus / Generic Mfg.
    Fibrosing Cholestatic Hepatitis Following Transplantation of a Hepatits C Virus Positive Donor Liver (Exhibit Halls 3 and 4 (Street Level)) -  Aug 8, 2019 - Abstract #ACG2019ACG_2995;    
    His course was complicated by multifocal HCC, for which he received treatments with DEB-TACE and Y90...The patient was treated with Epclusa for HCV and immunosuppression (prednisone, tacrolimus) for ACR with improvement in his liver enzymes...This ultimately leads to acute liver failure and may result in rapid graft loss. Given the high rates of mortality associated with FSC, prompt diagnosis and treatment with direct-acting antiviral regimens may be effective in treatment, even in severe cases.
  • ||||||||||  Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma, Sovaldi (sofosbuvir) / Gilead
    Enrollment open:  SCALE-C: Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination (clinicaltrials.gov) -  Aug 7, 2019   
    P=N/A,  N=600, Recruiting, 
    Given the high rates of mortality associated with FSC, prompt diagnosis and treatment with direct-acting antiviral regimens may be effective in treatment, even in severe cases. Not yet recruiting --> Recruiting
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  CRUSADE-1: Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet (clinicaltrials.gov) -  Aug 7, 2019   
    P4,  N=0, Withdrawn, 
    Not yet recruiting --> Recruiting N=14 --> 0 | Trial completion date: Dec 2020 --> Mar 2019 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2020 --> Mar 2019
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Trial completion date, Trial primary completion date:  Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia (clinicaltrials.gov) -  Aug 6, 2019   
    P2/3,  N=10, Completed, 
    N=14 --> 0 | Trial completion date: Dec 2020 --> Mar 2019 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2020 --> Mar 2019 Recruiting --> Completed | Trial completion date: Apr 2019 --> Jul 2019 | Trial primary completion date: Apr 2019 --> Jul 2019
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Enrollment open, Trial completion date, Trial primary completion date:  Expanding the Pool in Lung Transplantation (clinicaltrials.gov) -  Aug 6, 2019   
    P1,  N=20, Recruiting, 
    Recruiting --> Completed | Trial completion date: Apr 2019 --> Jul 2019 | Trial primary completion date: Apr 2019 --> Jul 2019 Not yet recruiting --> Recruiting | Trial completion date: Feb 2020 --> Feb 2026 | Trial primary completion date: Feb 2020 --> Feb 2021
  • ||||||||||  Trial completion date, Trial primary completion date:  KeY Treat: The Kentucky Viral Hepatitis Treatment Study (clinicaltrials.gov) -  Jul 28, 2019   
    P4,  N=900, Not yet recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Feb 2020 --> Feb 2026 | Trial primary completion date: Feb 2020 --> Feb 2021 Trial completion date: May 2024 --> Jul 2023 | Trial primary completion date: May 2023 --> Aug 2022
  • ||||||||||  ribavirin / Generic mfg.
    Trial completion date, Trial primary completion date:  MINMON: Monitoring SOF/VEL in Treatment Na (clinicaltrials.gov) -  Jul 8, 2019   
    P4,  N=400, Recruiting, 
    Trial completion date: May 2024 --> Jul 2023 | Trial primary completion date: May 2023 --> Aug 2022 Trial completion date: Apr 2022 --> Dec 2020 | Trial primary completion date: Apr 2022 --> Dec 2020
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Enrollment change, Trial completion date, Trial initiation date, Trial withdrawal:  Hepatitis C Positive Donor Into Hepatitis C Negative Recipients (clinicaltrials.gov) -  Jul 5, 2019   
    P1,  N=0, Withdrawn, 
    Trial completion date: Apr 2022 --> Dec 2020 | Trial primary completion date: Apr 2022 --> Dec 2020 N=50 --> 0 | Trial completion date: Dec 2019 --> Jul 2019 | Initiation date: Feb 2019 --> Jul 2019 | Not yet recruiting --> Withdrawn
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Enrollment change:  Expanding the Pool in Lung Transplantation (clinicaltrials.gov) -  Jul 1, 2019   
    P1,  N=20, Not yet recruiting, 
    N=50 --> 0 | Trial completion date: Dec 2019 --> Jul 2019 | Initiation date: Feb 2019 --> Jul 2019 | Not yet recruiting --> Withdrawn N=100 --> 20
  • ||||||||||  Copegus (ribavirin) / Bausch Health
    Review, Journal:  Sofosbuvir-velpatasvir: A single-tablet treatment for hepatitis C infection of all genotypes. (Pubmed Central) -  May 26, 2019   
    Sofosbuvir-velpatasvir is a DAA and the first single-tablet regimen to treat HCV infection caused by all genotypes. The efficacy and tolerability of sofosbuvir-velpatasvir have been observed in patients with types of HCV infection that traditionally have been difficult to treat.
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Trial completion date, Trial primary completion date:  Lung Transplant HCV, Pilot Study (clinicaltrials.gov) -  May 8, 2019   
    P1,  N=20, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Apr 2018 --> Oct 2019
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Trial completion date, Trial primary completion date:  The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients (clinicaltrials.gov) -  May 2, 2019   
    P2,  N=60, Not yet recruiting, 
    Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Apr 2018 --> Oct 2019 Trial completion date: Feb 2024 --> May 2024 | Trial primary completion date: Feb 2024 --> May 2024